Heart Views · May 2026

Prescribed But Not Pursued: Low-density Lipoprotein Cholesterol Target Attainment, Monitoring gaps, and Therapeutic Inertia after Percutaneous Coronary Intervention in Bahrain

By Hamad AK, Hasan AA, Alsabea AS et al.

Background: The 2019 European Society of Cardiology (ESC) guidelines recommend a low-density lipoprotein cholesterol (LDL-C) target of <1.4 mmol/L, with a ≥50% reduction from baseline, for very-high-risk patients, including those undergoing percutaneous coronary intervention (PCI). Real-world attainment data from the Arabian Gulf are limited. Materials and Methods: We conducted a retrospective cohort study of all 358 consecutive patients who underwent PCI at a tertiary cardiac center in Bahrain between January and March 2022. After excluding 154 without follow-up data, 204 were analyzed. The primary outcome was achievement of the ESC LDL-C target across follow-up visits. Secondary outcomes were lipid monitoring frequency, therapeutic intensification when off-target, predictors of failure, and crude 1-year event rates. Proportions are reported with Wilson 95% confidence intervals (CIs). Results: The cohort was predominantly male (86.8%), with diabetes (57.4%) and hypertension (62.7%). At discharge, 97.5% received high-intensity statins and 66.2% ezetimibe. The mean LDL-C fell from 3 to 2 mmol/L by the third follow-up, yet target attainment remained low (18.5%, 18.2%, and 24.1% at visits 1–3). Fewer than half (52.9%) had any repeat lipid measurement. When off-target, therapy was intensified in only 20.8% of cases (25/120). Higher baseline LDL-C independently predicted failure (odds ratio: 2.07 per 1 mmol/L; 95% CI: 1.19–3.58). Within 1 year, 11.8% had a recurrent coronary event. Conclusions: Despite excellent discharge prescribing, ESC LDL-C target attainment after PCI was poor, with infrequent monitoring and low treatment intensification. A structured post-PCI lipid pathway is needed.

doi.org/10.4103/heartviews.heartviews_173_26Open accessPopulations

AgingResearch.News